Frontlight ResearchEarly access
Triple-negative breast cancer trials in China
13 of 133 trials · From ClinicalTrials.gov, checked 17 November 2026. Ask the study team whether a trial fits you.
- No phaseTaking peoplePre-Treatment Breast DCE-MRI AI Model to Predict Neoadjuvant Chemotherapy Benefit in Locally Advanced Triple-Negative Breast Cancer
- Where
- Fuzhou, Ningde, Quanzhou, Sanming
- Age
- 18 years and over
- People
- 120
- Run by
- Fujian Cancer Hospital
See details and how to joinNCT07880600 - No phaseTaking peopleEstablishment of a Multi-omics Prediction Model for Early Triple-negative Breast Cancer Based on UPGRADE-TNBC Study
- Where
- Beijing
- Age
- 18 years to 75 years
- People
- 32
- Run by
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
See details and how to joinNCT07773818 - No phaseTaking peopleGranzyme B-PET: Predicting Immunotherapy Efficacy in TNBC
- Where
- Shanghai
- Age
- 18 years and over
- People
- 30
- Run by
- Fudan University
See details and how to joinNCT07705438 - No phaseTaking peopleReal-world Patient-reported Outcome of Sacituzumab Govitecan in Chinese Metastatic Breast Cancer
- Where
- Shanghai
- Age
- 18 years to 75 years
- People
- 300
- Run by
- Fudan University
See details and how to joinNCT07551050 - No phaseNot yet taking people in ChinaComparison of Chemotherapy and Immunotherapy in Neoadjuvant Therapy for TNBC
- Where
- Nanjing
- Age
- 18 years and over
- People
- 201
- Run by
- The First Affiliated Hospital with Nanjing Medical University
See details and how to joinNCT07523789 - No phaseTaking peoplePsychological State, Immunotherapy Response, and Multi-Omics Signatures in TNBC
- Where
- Shanghai
- Age
- 18 years to 70 years
- People
- 120
- Run by
- Fudan University
See details and how to joinNCT07290153 - No phaseTaking peopleReal-World Study of Post-Resistance Treatment Strategies in Advanced Breast Cancer Following CDK4/6i, PIK3CA Inhibitors, or T-DXd
- Where
- Changsha
- Age
- 18 years and over
- People
- 200
- Run by
- Hunan Cancer Hospital
See details and how to joinNCT07073755 - No phaseTaking peopleSacituzumab Govitecan + Toripalimab as First - Line Therapy for Advanced Triple - Negative Breast Cancer and Biomarker Exploration
- Where
- Beijing
- Age
- 18 years to 75 years
- People
- 51
- Run by
- Peking University Cancer Hospital & Institute
See details and how to joinNCT06991790 - No phaseNot yet taking people in ChinaReal-world Patient-reported Outcome of Sacituzumab Govitecan in Chinese Metastatic Triple-negative Breast Cancer
- Where
- Shanghai
- Age
- 18 years and over
- People
- 300
- Run by
- Fudan University
See details and how to joinNCT06798506 - No phaseTaking peopleDifferent Methods of Capecitabine in Patients With Non-PCR After Neoadjuvant Therapy for TNBC
- Where
- Beijing
- People
- 1,166
- Run by
- Shu Wang
See details and how to joinNCT06700382 - No phaseTaking peopleDe-escalation of Neoadjuvant Chemotherapy Regimens With Immunotherapy Among TNBC
- Where
- Beijing
- People
- 380
- Run by
- Peking University People's Hospital
See details and how to joinNCT06692725 - No phaseTaking peoplea Single-arm, Single-center, Open Clinical Study
- Where
- Zhengzhou
- Age
- 18 years to 75 years
- People
- 10
- Run by
- Beijing Geekgene Technology Co., LTD
See details and how to joinNCT06431100 - No phaseTaking peopleEstrogen Receptor (ER) PET/CT Imaging in Breast Cancer
- Where
- Wuhan
- Age
- 18 years and over
- People
- 80
- Run by
- Tongji Hospital
See details and how to joinNCT05541367